Literature DB >> 29397119

The hip fracture surgery in elderly patients (HIPELD) study to evaluate xenon anaesthesia for the prevention of postoperative delirium: a multicentre, randomized clinical trial.

M Coburn1, R D Sanders2, M Maze3, M-L Nguyên-Pascal4, S Rex5, B Garrigues6, J A Carbonell6, M L Garcia-Perez6, A Stevanovic7, P Kienbaum8, M Neukirchen8, M S Schaefer8, B Borghi9, H van Oven10, A Tognù10, L Al Tmimi5, L Eyrolle11, O Langeron12, X Capdevila13, G M Arnold14, M Schaller4, R Rossaint7.   

Abstract

BACKGROUND: Postoperative delirium occurs frequently in elderly hip fracture surgery patients and is associated with poorer overall outcomes. Because xenon anaesthesia has neuroprotective properties, we evaluated its effect on the incidence of delirium and other outcomes after hip fracture surgery.
METHODS: This was a phase II, multicentre, randomized, double-blind, parallel-group, controlled clinical trial conducted in hospitals in six European countries (September 2010 to October 2014). Elderly (≥75yr-old) and mentally functional hip fracture patients were randomly assigned 1:1 to receive either xenon- or sevoflurane-based general anaesthesia during surgery. The primary outcome was postoperative delirium diagnosed through postoperative day 4. Secondary outcomes were delirium diagnosed anytime after surgery, postoperative sequential organ failure assessment (SOFA) scores, and adverse events (AEs).
RESULTS: Of 256 enrolled patients, 124 were treated with xenon and 132 with sevoflurane. The incidence of delirium with xenon (9.7% [95% CI: 4.5 -14.9]) or with sevoflurane (13.6% [95% CI: 7.8 -19.5]) were not significantly different (P=0.33). Overall SOFA scores were significantly lower with xenon (least-squares mean difference: -0.33 [95% CI: -0.60 to -0.06]; P=0.017). For xenon and sevoflurane, the incidence of serious AEs and fatal AEs was 8.0% vs 15.9% (P=0.05) and 0% vs 3.8% (P=0.06), respectively.
CONCLUSIONS: Xenon anaesthesia did not significantly reduce the incidence of postoperative delirium after hip fracture surgery. Nevertheless, exploratory observations concerning postoperative SOFA-scores, serious AEs, and deaths warrant further study of the potential benefits of xenon anaesthesia in elderly hip fracture surgery patients. CLINICAL TRIAL REGISTRATION: EudraCT 2009-017153-35; ClinicalTrials.gov NCT01199276.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  aged; anaesthesia, general; delirium; hip fractures; xenon

Mesh:

Substances:

Year:  2017        PMID: 29397119     DOI: 10.1016/j.bja.2017.11.015

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  10 in total

1.  [Surgical treatment of proximal femoral fractures in high-risk geriatric patients under peripheral regional anesthesia : A clinical case series].

Authors:  R Seidel; E Barbakow
Journal:  Anaesthesist       Date:  2019-02-05       Impact factor: 1.041

2.  American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Postoperative Delirium Prevention.

Authors:  Christopher G Hughes; Christina S Boncyk; Deborah J Culley; Lee A Fleisher; Jacqueline M Leung; David L McDonagh; Tong J Gan; Matthew D McEvoy; Timothy E Miller
Journal:  Anesth Analg       Date:  2020-06       Impact factor: 5.108

3.  Effects of perioperative interventions for preventing postoperative delirium: A protocol for systematic review and meta-analysis of randomized controlled trials.

Authors:  Xia Li; Yanting Wang; Jie Liu; Yue Xiong; Shiqiang Chen; Jingjing Han; Wanli Xie; Qingping Wu
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 4.  Perioperative neurocognitive disorders: A narrative review focusing on diagnosis, prevention, and treatment.

Authors:  Hao Kong; Long-Ming Xu; Dong-Xin Wang
Journal:  CNS Neurosci Ther       Date:  2022-06-01       Impact factor: 7.035

5.  Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial.

Authors:  Ting Li; Jun Li; Liyong Yuan; Jinze Wu; Chenchen Jiang; Jane Daniels; Rajnikant Laxmishanker Mehta; Mingcang Wang; Joyce Yeung; Thomas Jackson; Teresa Melody; Shengwei Jin; Yinguang Yao; Jimin Wu; Junping Chen; Fang Gao Smith; Qingquan Lian
Journal:  JAMA       Date:  2022-01-04       Impact factor: 157.335

Review 6.  Disease Mechanisms of Perioperative Organ Injury.

Authors:  Catharina Conrad; Holger K Eltzschig
Journal:  Anesth Analg       Date:  2020-12       Impact factor: 6.627

Review 7.  Anesthetic management of geriatric patients.

Authors:  Byung-Gun Lim; Il-Ok Lee
Journal:  Korean J Anesthesiol       Date:  2019-10-22

8.  Improve hip fracture outcome in the elderly patient (iHOPE): a study protocol for a pragmatic, multicentre randomised controlled trial to test the efficacy of spinal versus general anaesthesia.

Authors:  Ana Kowark; Christian Adam; Jörg Ahrens; Malek Bajbouj; Cornelius Bollheimer; Matthias Borowski; Richard Dodel; Michael Dolch; Thomas Hachenberg; Dietrich Henzler; Frank Hildebrand; Ralf-Dieter Hilgers; Andreas Hoeft; Susanne Isfort; Peter Kienbaum; Mathias Knobe; Pascal Knuefermann; Peter Kranke; Rita Laufenberg-Feldmann; Carla Nau; Mark D Neuman; Cynthia Olotu; Christopher Rex; Rolf Rossaint; Robert D Sanders; Rene Schmidt; Frank Schneider; Hartmut Siebert; Max Skorning; Claudia Spies; Oliver Vicent; Frank Wappler; Dieter Christian Wirtz; Maria Wittmann; Kai Zacharowski; Alexander Zarbock; Mark Coburn
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

9.  Noble gas neuroprotection: xenon and argon protect against hypoxic-ischaemic injury in rat hippocampus in vitro via distinct mechanisms.

Authors:  Mariia Koziakova; Katie Harris; Christopher J Edge; Nicholas P Franks; Ian L White; Robert Dickinson
Journal:  Br J Anaesth       Date:  2019-08-27       Impact factor: 9.166

Review 10.  Update of the organoprotective properties of xenon and argon: from bench to beside.

Authors:  Roehl Anna; Rossaint Rolf; Coburn Mark
Journal:  Intensive Care Med Exp       Date:  2020-02-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.